Clinical trials: Multiple Myeloma With Failed Remission
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma Stage II, Multiple Myeloma Stage I
- Trial name
- RithMM (NCT03428373)
- Testing
- Rivaroxaban, ASA
- Where
- Canada
- Volunteers
- 57 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Myeloma in Relapse, Plasmacytoma
Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma
This trial aimed to investigate the therapeutic efficacy of daratumumnab plus chemitherapy in multiple myeloma with plasmacytoma.
- Conditions
- Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab
- Trial name
- Dara_DCEP (NCT04065308)
- Testing
- Drug Combinations
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Seoul National University Hospital
Multiple Myeloma, Multiple Myeloma in Relapse
A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma With Failed Remission
- Trial name
- NCT03650491
- Testing
- FOR46
- Where
- 7 sites in United States
- Volunteers
- 31 people
- Sponsor
- Fortis Therapeutics, Inc.
Multiple Myeloma in Relapse, Multiple Myeloma
Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma
The goal of this pilot study is to evaluate the impact of All4Cure enrollment on patients with multiple myeloma. The main question it aims to answer are: Does All4Cure effect patient activation as assessed by the PAM-13 survey?…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma, Refractory, Multiple Myeloma With Failed Remission
- Trial name
- NCT05673083
- Where
- 7 sites in United States
- Volunteers
- 200 people
- Sponsor
- All4Cure
Multiple Myeloma in Relapse, Multiple Myeloma Progression
Tinostamustine Conditioning and Autologous Stem Cell
Phase 1 The primary objectives of Phase 1 of this study are to: Establish the safety, toxicity, and maximum tolerated dose (MTD) of the tinostamustine conditioning regimen.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma Progression, Multiple Myeloma With Failed Remission
- Trial name
- TITANIUM1 (NCT03687125)
- Testing
- Tinostamustine, Autologous Stem Cell Transplant (ASCT)
- Where
- 12 sites in United States, Norway and 1 more
- Volunteers
- 6 people
- Sponsor
- Mundipharma-EDO GmbH
Myeloma
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
- Trial name
- NCT01174082
- Testing
- KLH Vaccine, KLH-id Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma in Relapse, Multiple Myeloma
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people…
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
- Trial name
- NCT04184050
- Testing
- MK-4002
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)